Ask AI
ProCE Banner Activity

CE

Addressing Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know

eCourse

Addressing Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know

Physicians: maximum of 1.00 AMA PRA Category 1 Credit(s)

Released: June 22, 2026

Expiration: June 22, 2027

Share

Learning Objectives

  • Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression in order to improve the identification of MASH

  • Recognize current and emerging approaches and tools to screen and diagnose MAFLD and MASH in clinical practice

  • Summarize the current guidelines and recommendations for treatment of MASH, including recent consensus statements

  • Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of MASH

  • List emerging MASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression

Financial Disclosures

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Additional Disclosures

PACE Disclaimer